Distribution of human CYP2C8*2 allele in three different African populations

Malaria Journal

Volumn 11, Issue , 2012, Pages

  Paganotti, Giacomo M ^a   Gramolelli, Silvia ^a   Tabacchi, Francesca ^a   Russo, Gianluca ^a   Modiano, David ^a   Coluzzi, Mario ^a   Romano, Rita ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

2 allele; Africa; Amodiaquine; Chloroquine; CYP2C8; CYP2C8 enzyme; Drug resistance; Plasmodium falciparum malaria; Poor metabolizers

Indexed keywords

CYTOCHROME P450 2C8; AMODIAQUINE; ANTIMALARIAL AGENT; CHLOROQUINE; CYP2C8 PROTEIN, HUMAN; UNSPECIFIC MONOOXYGENASE;

ADOLESCENT; ARTICLE; CHILD; GENE FREQUENCY; HUMAN; MADAGASCAR; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; POLYMERASE CHAIN REACTION; SCHOOL CHILD; SENEGAL; SINGLE NUCLEOTIDE POLYMORPHISM; UGANDA; WILD TYPE; CROSS-SECTIONAL STUDY; FEMALE; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; MALE; METABOLISM; PRESCHOOL CHILD; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADOLESCENT; AMODIAQUINE; ANTIMALARIALS; ARYL HYDROCARBON HYDROXYLASES; CHILD; CHILD, PRESCHOOL; CHLOROQUINE; CROSS-SECTIONAL STUDIES; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MADAGASCAR; MALE; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; SENEGAL; UGANDA;

EID: 84860195435     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-11-125     Document Type: Article

References (32)

1. The anatomy of a malaria disaster: drug policy choice and mortality in African children. Hastings IM, Korenromp EL, Bloland PB, Lancet Infect Dis 2007 7 739 748 10.1016/S1473-3099(07)70214-1 17884732 (Pubitemid 47610756)
2. Spread and evolution of Plasmodium falciparum drug resistance. Mita T, Tanabe K, Kita K, Parasitol Int 2009 58 201 209 10.1016/j.parint.2009.04.004 19393762
3. Human genetic variation is associated with Plasmodium falciparum drug-resistance. Paganotti GM, Gallo BC, Verra F, Sirima BS, Nebié I, Diarra A, Coluzzi M, Modiano D, J Infect Dis 2011 204 1772 1778 10.1093/infdis/jir629 21998472
4. Cytochrome P450 2 C8: substrates, inhibitors, pharmacogenetics, and clinical relevance. Totah RA, Rettie AE, Clin Pharmacol Ther 2005 77 341 352 10.1016/j.clpt.2004.12.267 15900280 (Pubitemid 40719263)
5. Cytochrome P450 2 C8 and CYP3A4/5 are involved in chloroquine metabolism in human liver microsomes. Kim KA, Park JY, Lee JS, Lim S, Arch Pharm Res 2003 26 631 637 10.1007/BF02976712 12967198 (Pubitemid 43080195)
6. In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation. Projean D, Baune B, Farinotti R, Flinois JP, Beaune P, Taburet AM, Ducharme J, Drug Metab Dispos 2003 31 748 754 10.1124/dmd.31.6.748 12756207 (Pubitemid 36617663)
7. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP, J Pharmacol Exp Ther 1994 270 414 423 8035341 (Pubitemid 24229655)
8. Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4. Zeigler-Johnson CM, Walker AH, Mancke B, Spangler E, Jalloh M, McBride S, Deitz A, Malkowicz SB, Ofori-Adjei D, Gueye SM, Rebbeck TR, Hum Hered 2002 54 13 21 10.1159/000066695 12446983 (Pubitemid 35404245)
9. CYP2C8 polymorphism frequencies among malaria patients in Zanzibar. Cavaco I, Strömberg-Nörklit J, Kaneko A, Msellem MI, Dahoma M, Ribeiro VL, Bjorkman A, Gil JP, Eur J Clin Pharmacol 2005 61 15 18 10.1007/s00228-004- 0871-8 15785959 (Pubitemid 40558274)
10. CYP3A4 and CYP3A5 genotyping by Pyrosequencing. Garsa AA, McLeod HL, Marsh S, BMC Med Genet 2005 9 6 19
11. Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda. Penzak SR, Kabuye G, Mugyenyi P, Mbamanya F, Natarajan V, Alfaro RM, Kityo C, Formentini E, Masur H, HIV Med 2007 8 86 91 10.1111/j.1468-1293.2007.00432.x 17352764 (Pubitemid 46390844)
12. Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa. Parikh S, Ouedraogo JB, Goldstein JA, Rosenthal PJ, Kroetz DL, Clin Pharmacol Ther 2007 82 197 203 10.1038/sj.clpt.6100122 17361129 (Pubitemid 47075331)
13. Application of pharmacogenomics to malaria: a holistic approach for successful chemotherapy. Mehlotra RK, Henry-Halldin CN, Zimmerman PA, Pharmacogenomics 2009 10 435 449 10.2217/14622416.10.3.435 19290792
14. Short communication: high prevalence of the cytochrome P450 2 C8*2 mutation in Northern Ghana. Röwer S, Bienzle U, Weise A, Lambertz U, Forst T, Otchwemah RN, Pfützner A, Mockenhaupt FP, Trop Med Int Health 2005 10 1271 1273 10.1111/j.1365-3156.2005.01525.x 16359408 (Pubitemid 41789681)
15. Effect of concomitant artesunate administration and cytochrome P4502C8 polymorphisms on the pharmacokinetics of amodiaquine in Ghanaian children with uncomplicated malaria. Adjei GO, Kristensen K, Goka BQ, Hoegberg LC, Alifrangis M, Rodrigues OP, Kurtzhals JA, Antimicrob Agents Chemother 2008 52 4400 4406 10.1128/AAC.00673-07 18779360
16. Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population. Kudzi W, Dodoo AN, Mills JJ, BMC Med Genet 2009 10 124 129 10.1186/1471-2350-10-124 19954515
17. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI, Goldstein JA, Pharmacogenetics 2001 11 597 607 10.1097/00008571-200110000-00006 11668219 (Pubitemid 32953585)
18. Patterns of chloroquine use and resistance in sub-Saharan Africa: a systematic review of household survey and molecular data. Frosch AE, Venkatesan M, Laufer MK, Malar J 2011 10 116 10.1186/1475-2875-10-116 21554692
19. Management of uncomplicated malaria in children under 13 years of age at a district hospital in Senegal: from official guidelines to usual practices. Sarrassat S, Lalou R, Cissé M, Le Hesran JY, Malar J 2011 10 285 10.1186/1475-2875-10-285 21958422
20. Got ACTs? Availability, price, market share and provider knowledge of anti-malarial medicines in public and private sector outlets in six malaria-endemic countries. O'Connell KA, Gatakaa H, Poyer S, Njogu J, Evance I, Munroe E, Solomon T, Goodman C, Hanson K, Zinsou C, Akulayi L, Raharinjatovo J, Arogundade E, Buyungo P, Mpasela F, Adjibabi CB, Agbango JA, Ramarosandratana BF, Coker B, Rubahika D, Hamainza B, Chapman S, Shewchuk T, Chavasse D, Malar J 2011 10 326 10.1186/1475-2875-10-326 22039838
21. Monitoring fever treatment behaviour and equitable access to effective medicines in the context of initiatives to improve ACT access: baseline results and implications for programming in six African countries. Littrell M, Gatakaa H, Evance I, Poyer S, Njogu J, Solomon T, Munroe E, Chapman S, Goodman C, Hanson K, Zinsou C, Akulayi L, Raharinjatovo J, Arogundade E, Buyungo P, Mpasela F, Adjibabi CB, Agbango JA, Ramarosandratana BF, Coker B, Rubahika D, Hamainza B, Shewchuk T, Chavasse D, O'Connell KA, Malar J 2011 10 327 10.1186/1475-2875-10- 327 22039892
22. World Health Organization, World malaria report. Geneva 2011
23. Quality of chloroquine tablets available in Africa. Sawadogo CW, Amood Al-Kamarany M, Al-Mekhlafi HM, Elkarbane M, Al-Adhroey AH, Cherrah Y, Bouklouze A, Ann Trop Med Parassito 2011 105
24. Poor quality vital anti-malarials in Africa-an urgent neglected public health priority. Newton PN, Green MD, Mildenhall DC, Plancon A, Nettey H, Nyadong L, Hostetler DM, Swamidoss I, Harris GA, Powell K, Timmermans AE, Amin AA, Opuni SK, Barbereau S, Faurant C, Soong RC, Faure K, Thevanayagam J, Fernandes P, Kaur H, Angus B, Stepniewska K, Guerin PJ, Fernandez FM, Malar J 2011 10 352 10.1186/1475-2875-10-352 22152094
25. Evaluation of bloodsucking arthropod bite as possible risk co-factor in Human herpesvirus-8 transmission route. Romano R, Tabacchi F, Paganotti GM, Russo G, Gramolelli S, Marinucci F, Ceccherini-Nelli L, Coluzzi M, Parassitologia 2010 52 417 422
26. Human Herpesvirus 8 (HHV-8): salivary shedding in mothers and children from Uganda: risk factors and clues about transmission. Romano R, Gramolelli S, Tabacchi F, Russo G, Verzaro S, Marinucci F, Paganotti GM, Gaeta A, Coluzzi M, Prevention and Research 2011 1 44 52
27. http://genepop.curtin.edu.au/
28. Malaria in Uganda: challenges to control on the long road to elimination: I. Epidemiology and current control efforts. Yeka A, Gasasira A, Mpimbaza A, Achan J, Nankabirwa J, Nsobya S, Staedke SG, Donnelly MJ, Wabwire-Mangen F, Talisuna A, Dorsey G, Kamya MR, Rosenthal PJ, Acta Trop 2012 121 184 195
29. Short report: polymorphisms in the pfcrt and pfmdr1 genes of Plasmodium falciparum and in vitro susceptibility to amodiaquine and desethylamodiaquine. Echeverry DF, Holmgren G, Murillo C, Higuita JC, Björkman A, Gil JP, Osorio L, Am J Trop Med Hyg 2007 77 1034 1038 18165517 (Pubitemid 351837788)
30. Chloroquine clinical failures in P. falciparum malaria are associated with mutant Pfmdr-1, not Pfcrt in Madagascar. Andriantsoanirina V, Ratsimbasoa A, Bouchier C, Tichit M, Jahevitra M, Rabearimanana S, Raherinjafy R, Mercereau-Puijalon O, Durand R, Ménard D, PLoS One 2010 5 13281 10.1371/journal.pone.0013281 20967251
31. Prevalent pfmdr1 n86y mutant Plasmodium falciparum in Madagascar despite absence of pfcrt mutant strains. Rason MA, Andrianantenaina HB, Ariey F, Raveloson A, Domarle O, Randrianarivelojosia M, Am J Trop Med Hyg 2007 76 1079 1083 17556614 (Pubitemid 351837869)
32. Estimation of effective population sizes from data on genetic markers. Wang J, Phil Trans R Soc B 2005 360 1395 1409 10.1098/rstb.2005.1682 16048783 (Pubitemid 43138543)